Targets › RARA
14 programs from 13 companies in 34 trials: 23 Phase 2, 4 Phase 3, 4 Phase 4, 3 Phase 1; Oncology, Immunology, Infectious disease; next expected readout Dec 2026.
Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. (UniProt, P10276)
Open in Phaseline: the race on RARA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| IR INNOVATE RESEARCH PRIVATE | Adapalene Retinoic acid receptor agonist | RARG, RARB, RARA | Phase 4 | Acne; Viral Warts | Feb 2027 |
| Centre Hospitalier Universitaire de Nice | Isotretinoin Retinoic acid receptor agonist | RARG, RARB, RARA | Phase 3 | Acne Vulgaris | Sep 2027 |
| Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | ATRA (All-trans retinoic acid) Retinoic acid receptor agonist | RARA, RARB, RARG | Phase 2 | Oral Cavity Cancer | Dec 2026 |
| Nagoya University | tamivarotene (AM80) Retinoic acid receptor alpha (RARα) agonist | RARA | Phase 2 | Urothelial Carcinoma Bladder | Mar 2027 |
| St. Petersburg State Pavlov Medical University | Vitamin A Retinoid receptor agonist; supports immune tolerance and graft-versus-host disease prevent | RARA, RARB, RARG | Phase 2 | Acute Lymphoblastic Leukemia | May 2027 |
| Children's Hospital Medical Center, Cincinnati | Vitamin A Retinoid receptor ligand; immunomodulatory effects on T cell differentiation and GVHD | RXRA, RXRB, RXRG, RARA, RARB | Phase 2 | Graft Vs Host Disease | Aug 2027 |
| Children's Oncology Group | Isotretinoin Retinoic acid receptor agonist | RARG, RARB, RARA | Phase 2 | Ganglioneuroblastoma, Nodular | Sep 2027 |
| Instituto do Cancer do Estado de São Paulo | ATRA (All-trans retinoic acid) Retinoic acid receptor agonist; induces differentiation of APL cells and degradation of PM | RARA | Phase 2 | Acute Promyelocytic Leukemia (APL) | Nov 2028 |
| Instituto do Cancer do Estado de São Paulo | Realgar-Indigo Naturalis Formulation (Oral Arsenic) Arsenic trioxide induces differentiation and apoptosis of acute promyelocytic leukemia cel | PML, RARA | Phase 2 | Acute Promyelocytic Leukemia (APL) | Nov 2028 |
| HighField Biopharmaceuticals | Tretinoin Retinoic acid receptor agonist | RARG, RARB, RARA | Phase 2 | Glioma; Acne Vulgaris; Melasma (Facial Melasma); APL … | Dec 2028 |
| Fudan University | All Trans Retinoic Acid (ATRA) Retinoic acid receptor agonist | RARA, RARB, RARG | Phase 2 | Triple Negative Breast Cancer (TNBC) | Sep 2029 |
| Rege Nephro | Tamibarotene Retinoic acid receptor beta agonist; Retinoic acid receptor alpha agonist | RARB, RARA | Phase 2 | Autosomal Dominant Polycystic Kidney Disease (ADPKD); HFpEF - Heart Failure With Preserved Ejection Fraction | – |
| Zagazig University | Isotretinoin Retinoic acid receptor agonist | RARG, RARB, RARA | Phase 1 | Onychomycosis | Dec 2026 |
| National Cancer Institute (NCI) | Isotretinoin Retinoic acid receptor agonist | RARG, RARB, RARA | Phase 1 | Recurrent Neuroblastoma | Mar 2027 |
Acute Promyelocytic Leukemia (APL) (2) Acne Vulgaris (2) Glioma (2) Persistent Isolated Chemotherapy-Induced Thrombocytopenia (2) Recurrent Neuroblastoma (1) Onychomycosis (1) Urothelial Carcinoma Bladder (1) Acne (1) Viral Warts (1) Melasma (Facial Melasma) (1) APL (1) Oropharynx Cancer (1)
small molecule (9), antibody (3), mixed (2)
Instituto do Cancer do Estado de São Paulo (2) National Cancer Institute (NCI) (1) Zagazig University (1) Centre Hospitalier Universitaire de Nice (1) Nagoya University (1) IR INNOVATE RESEARCH PRIVATE (1) HighField Biopharmaceuticals (1) Children's Oncology Group (1) Children's Hospital Medical Center, Cincinnati (1) Fudan University (1) St. Petersburg State Pavlov Medical University (1) Rege Nephro (1) Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.